Published in J Acquir Immune Defic Syndr on July 01, 1999
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (2000) 3.39
Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis (2007) 2.34
Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS (2002) 1.79
The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS (2004) 1.64
Independent associations of insulin resistance with high whole-body intermuscular and low leg subcutaneous adipose tissue distribution in obese HIV-infected women. Am J Clin Nutr (2007) 1.63
HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes (2003) 1.25
Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice. J Biol Chem (2010) 0.94
Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy. AIDS (2008) 0.91
HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus. Am J Physiol Endocrinol Metab (2008) 0.91
An inhibitor of HIV-1 protease modulates constitutive eIF2α dephosphorylation to trigger a specific integrated stress response. Proc Natl Acad Sci U S A (2015) 0.90
HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters. Biochim Biophys Acta (2010) 0.88
Post-exercise heart rate recovery in HIV-positive individuals on highly active antiretroviral therapy. Early indicator of cardiovascular disease? HIV Med (2007) 0.87
HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models. Curr Opin HIV AIDS (2008) 0.84
Insulin resistance by homeostasis model assessment in HIV-infected patients on highly active antiretroviral therapy: cross-sectional study. Diabetol Metab Syndr (2015) 0.83
Sequence-specific alterations of epitope production by HIV protease inhibitors. J Immunol (2014) 0.83
Direct interference of HIV protease inhibitors with pancreatic beta-cell function. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.82
Protease inhibitors used in the treatment of HIV+ induce beta-cell apoptosis via the mitochondrial pathway and compromise insulin secretion. Am J Physiol Endocrinol Metab (2009) 0.81
Blunted lipolysis and fatty acid oxidation during moderate exercise in HIV-infected subjects taking HAART. Am J Physiol Endocrinol Metab (2006) 0.81
Effects of human immunodeficiency virus and metabolic complications on myocardial nutrient metabolism, blood flow, and oxygen consumption: a cross-sectional analysis. Cardiovasc Diabetol (2011) 0.81
Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic Analysis. Metab Syndr Relat Disord (2007) 0.79
Optimal timing and duration of induction therapy for HIV-1 infection. PLoS Comput Biol (2007) 0.79
Hyperglycemia enhances kidney cell injury in HIVAN through down-regulation of vitamin D receptors. Cell Signal (2014) 0.79
Risk factors for new-onset diabetes mellitus in patients receiving protease inhibitor therapy. Can J Infect Dis Med Microbiol (2005) 0.78
Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers. J Acquir Immune Defic Syndr (2010) 0.77
Pilot study of pioglitazone and exercise training effects on basal myocardial substrate metabolism and left ventricular function in HIV-positive individuals with metabolic complications. HIV Clin Trials (2013) 0.76
Relationships among HIV infection, metabolic risk factors, and left ventricular structure and function. AIDS Res Hum Retroviruses (2013) 0.75
Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial. HIV Clin Trials (2016) 0.75
Brain GLUT4 Knockout Mice Have Impaired Glucose Tolerance, Decreased Insulin Sensitivity, and Impaired Hypoglycemic Counterregulation. Diabetes (2016) 0.75
Use Your Words Carefully: What Is a Chronic Disease? Front Public Health (2016) 0.75
Insulin resistance and associated factors among HIV-infected patients in sub-Saharan Africa: a cross sectional study from Cameroon. Lipids Health Dis (2017) 0.75
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med (1997) 17.51
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 8.88
Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med (1994) 6.59
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
HIV-protease inhibitors. N Engl J Med (1998) 4.42
"Buffalo hump" in men with HIV-1 infection. Lancet (1998) 3.93
Severe diabetes associated with protease inhibitor therapy. Ann Intern Med (1997) 2.71
Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. MMWR Recomm Rep (1998) 2.06
Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS (1998) 2.05
Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest (1997) 1.63
Brief report: impaired processing of prohormones associated with abnormalities of glucose homeostasis and adrenal function. N Engl J Med (1995) 1.39
Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS (1999) 1.34
Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia (1987) 1.34
Function and inhibition of intracellular calcium-independent phospholipase A2. J Biol Chem (1997) 1.34
Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes (1997) 1.34
Pancreatic islets express a Ca2+-independent phospholipase A2 enzyme that contains a repeated structural motif homologous to the integral membrane protein binding domain of ankyrin. J Biol Chem (1997) 1.31
Inhibition of arachidonate release by secretagogue-stimulated pancreatic islets suppresses both insulin secretion and the rise in beta-cell cytosolic calcium ion concentration. Biochemistry (1993) 1.22
Glucocorticoid-induced insulin resistance: dexamethasone inhibits the activation of glucose transport in rat skeletal muscle by both insulin- and non-insulin-related stimuli. Diabetes (1995) 1.13
The relation of proinsulin, insulin, and proinsulin-to-insulin ratio to insulin sensitivity and acute insulin response in normoglycemic subjects. Diabetes (1997) 1.09
New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med (1997) 1.05
Levels of the conversion endoproteases PC1 (PC3) and PC2 distinguish between insulin-producing pancreatic islet beta cells and non-beta cells. Biochem J (1994) 0.99
Proinsulin processing in the rat insulinoma cell line INS after overexpression of the endoproteases PC2 or PC3 by recombinant adenovirus. Biochem J (1996) 0.97
Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome. J Clin Endocrinol Metab (1994) 0.94
Slow cleavage at the proinsulin B-chain/connecting peptide junction associated with low levels of endoprotease PC1/3 in transformed beta cells. J Biol Chem (1993) 0.94
Purification and characteristics of the candidate prohormone processing proteases PC2 and PC1/3 from bovine adrenal medulla chromaffin granules. J Biol Chem (1995) 0.90
Halo enol lactones: studies on the mechanism of inactivation of alpha-chymotrypsin. Biochemistry (1986) 0.89
Insulin resistance does not change the ratio of proinsulin to insulin in normal volunteers. J Clin Endocrinol Metab (1997) 0.89
Effect of insulin resistance and hyperglycemia on proinsulin release in a primate model of diabetes mellitus. J Clin Endocrinol Metab (1992) 0.84
Protease inhibitors and drug interactions--an alert. J Clin Psychopharmacol (1996) 0.80
Arachidonic acid metabolism. Annu Rev Biochem (1986) 6.56
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med (1992) 5.84
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med (1990) 5.55
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology (1992) 5.45
Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA (2001) 3.73
Proliferation of sorted human and rat beta cells. Diabetologia (2007) 3.56
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (2000) 3.39
Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother (1990) 3.26
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA (2000) 2.91
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med (1995) 2.88
Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med (1976) 2.72
Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest (1989) 2.69
Insulin independence after islet transplantation into type I diabetic patient. Diabetes (1990) 2.57
Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. J Clin Invest (1980) 2.57
Physiology and pathophysiology of the human sympathoadrenal neuroendocrine system. N Engl J Med (1980) 2.55
An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet (2003) 2.43
Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest (1993) 2.35
Pulmonary cryptococcosis in patients without HIV infection. Chest (1999) 2.31
Thyroid function during pregnancy. Clin Chem (1999) 2.30
Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes (1991) 2.17
Perioperative management of surgical patients with diabetes mellitus. Anesthesiology (1991) 2.11
Sex differences in nevirapine rash. Clin Infect Dis (2000) 2.09
Characterization of phosphatidylinositol, phosphatidylinositol-4-phosphate, and phosphatidylinositol-4,5-bisphosphate by electrospray ionization tandem mass spectrometry: a mechanistic study. J Am Soc Mass Spectrom (2000) 2.03
A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med (1995) 1.89
Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med (1998) 1.88
Regulation of immunoreactive-insulin release from a rat cell line (RINm5F). Biochem J (1983) 1.85
Identification of type I diabetic patients at increased risk for hypoglycemia during intensive therapy. N Engl J Med (1983) 1.83
Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes (1994) 1.81
Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging (1996) 1.80
Amphotericin B: delivery systems. Antimicrob Agents Chemother (1990) 1.78
Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS. Clin Infect Dis (1993) 1.77
The effect of standard- and high-dose epinephrine on coronary perfusion pressure during prolonged cardiopulmonary resuscitation. JAMA (1991) 1.74
Importance of cell-matrix interactions in rat islet beta-cell secretion in vitro: role of alpha6beta1 integrin. Diabetes (2000) 1.71
Adrenergic mechanisms for the effects of epinephrine on glucose production and clearance in man. J Clin Invest (1980) 1.71
Structural characterization of triacylglycerols as lithiated adducts by electrospray ionization mass spectrometry using low-energy collisionally activated dissociation on a triple stage quadrupole instrument. J Am Soc Mass Spectrom (1999) 1.71
Intracellular Ca2+ mobilization by arachidonic acid. Comparison with myo-inositol 1,4,5-trisphosphate in isolated pancreatic islets. J Biol Chem (1986) 1.70
Electrospray ionization with low-energy collisionally activated dissociation tandem mass spectrometry of glycerophospholipids: mechanisms of fragmentation and structural characterization. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.69
Norepinephrine: hormone and neurotransmitter in man. Am J Physiol (1978) 1.66
Formation of lithiated adducts of glycerophosphocholine lipids facilitates their identification by electrospray ionization tandem mass spectrometry. J Am Soc Mass Spectrom (1998) 1.65
The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man. J Clin Invest (1976) 1.63
Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis (1998) 1.60
Charge-remote and charge-driven fragmentation processes in diacyl glycerophosphoethanolamine upon low-energy collisional activation: a mechanistic proposal. J Am Soc Mass Spectrom (2000) 1.60
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group. Ann Intern Med (1995) 1.59
Oligomerization of green fluorescent protein in the secretory pathway of endocrine cells. Biochem J (2001) 1.56
The possible importance of contact between pancreatic islet cells for the control of insulin release. Endocrinology (1982) 1.55
Serial plasma catecholamine response early in the course of clinical acute myocardial infarction: relationship to infarct extent and mortality. Am Heart J (1981) 1.54
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med (2008) 1.54
Perceived symptoms in the recognition of hypoglycemia. Diabetes Care (1993) 1.53
A new, rapid, method for preparation of dispersed pancreatic acini. Biochem J (1985) 1.53
Resistance to penicillin and non-beta-lactam antibiotics of Streptococcus pneumoniae at a children's hospital. Pediatr Infect Dis J (1994) 1.53
External and internal standards in the single-isotope derivative (radioenzymatic) measurement of plasma norepinephrine and epinephrine. J Lab Clin Med (1985) 1.52
Isotope-derivative measurements of plasma norepinephrine and epinephrine in man. Diabetes (1976) 1.52
Epinephrine, norepinephrine, glucagon, and growth hormone release in association with physiological decrements in the plasma glucose concentration in normal and diabetic man. J Clin Endocrinol Metab (1980) 1.50
SNAP-25 is expressed in islets of Langerhans and is involved in insulin release. J Cell Biol (1995) 1.48
The molecular biology of the group VIA Ca2+-independent phospholipase A2. Prog Nucleic Acid Res Mol Biol (2001) 1.48
Bacteremia in hospitalized patients infected with the human immunodeficiency virus: a case-control study of risk factors and outcome. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.47
Glucose counterregulation, hypoglycemia, and intensive insulin therapy in diabetes mellitus. N Engl J Med (1985) 1.47
Lipolysis during fasting. Decreased suppression by insulin and increased stimulation by epinephrine. J Clin Invest (1987) 1.47
Charge-driven fragmentation processes in diacyl glycerophosphatidic acids upon low-energy collisional activation. A mechanistic proposal. J Am Soc Mass Spectrom (2000) 1.46
Retracted Glucoregulation during exercise: hypoglycemia is prevented by redundant glucoregulatory systems, sympathochromaffin activation, and changes in islet hormone secretion. J Clin Invest (1986) 1.45
Identification and macrophage-activating activity of glycolipids released from intracellular Mycobacterium bovis BCG. Mol Microbiol (2003) 1.45
Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest (1987) 1.44
Newly synthesized proinsulin/insulin and stored insulin are released from pancreatic B cells predominantly via a regulated, rather than a constitutive, pathway. J Cell Biol (1987) 1.43
Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis (2006) 1.42
Variation in delayed hypersensitivity in onchocerciasis. Trans R Soc Trop Med Hyg (1978) 1.42
Intracellular degradation of insulin stores by rat pancreatic islets in vitro. An alternative pathway for homeostasis of pancreatic insulin content. J Biol Chem (1980) 1.40
Herpes simplex virus type 2 meningitis in the absence of genital lesions: improved recognition with use of the polymerase chain reaction. Clin Infect Dis (1995) 1.40
The fragile X continuum: new advances and perspectives. J Intellect Disabil Res (2008) 1.39
Resistance to amphotericin B associated with defective sterol delta 8-->7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol Lett (1994) 1.38
Prophylaxis and treatment of opportunistic infection in patients on HAART. AIDS Read (2003) 1.38
Measurement of norepinephrine and epinephrine in small volumes of human plasma by a single isotope derivative method: response to the upright posture. J Clin Endocrinol Metab (1974) 1.37
The preparation of a semisynthetic tritiated insulin with a specific radioactivity of up to 20 Curies per millimole. Biochem J (1975) 1.37
Glucose counterregulation in man. Diabetes (1981) 1.36
IL-1 beta induces the coexpression of both nitric oxide synthase and cyclooxygenase by islets of Langerhans: activation of cyclooxygenase by nitric oxide. Biochemistry (1993) 1.36
Long-term exposure of isolated pancreatic islets to mannoheptulose: evidence for insulin degradation in the beta cell. Biochem Pharmacol (1980) 1.35
Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes (1997) 1.34
Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells. J Biol Chem (1992) 1.33
Pancreatic islets express a Ca2+-independent phospholipase A2 enzyme that contains a repeated structural motif homologous to the integral membrane protein binding domain of ankyrin. J Biol Chem (1997) 1.31
Effect of short-term fasting on lipid kinetics in lean and obese women. Am J Physiol (1999) 1.31
Structural determination of sphingomyelin by tandem mass spectrometry with electrospray ionization. J Am Soc Mass Spectrom (2000) 1.31
Expression of neural cell adhesion molecule (N-CAM) in rat islets and its role in islet cell type segregation. J Cell Sci (1994) 1.31
Uvomorulin mediates calcium-dependent aggregation of islet cells, whereas calcium-independent cell adhesion molecules distinguish between islet cell types. Dev Biol (1991) 1.31
Arachidonic acid 15-lipoxygenase products from human eosinophils. J Biol Chem (1982) 1.30
Mucosal candidiasis caused by non-albicans species of Candida in HIV-positive patients. AIDS (1992) 1.29
A proposal for a standardized system of reporting human lymph node morphology in relation to immunological function. J Clin Pathol (1973) 1.29
Biphasic adrenergic modulation of beta-adrenergic receptors in man. Agonist-induced early increment and late decrement in beta-adrenergic receptor number. J Clin Invest (1980) 1.29
Plasma catecholamines in diabetes. The syndromes of hypoadrenergic and hyperadrenergic postural hypotension. Am J Med (1978) 1.29
Biochemical evidence for nitric oxide formation from streptozotocin in isolated pancreatic islets. Biochem Biophys Res Commun (1993) 1.29
Epinephrine and norepinephrine are cleared through beta-adrenergic, but not alpha-adrenergic, mechanisms in man. Metabolism (1980) 1.28
A pyrrolidine-based specific inhibitor of cytosolic phospholipase A(2)alpha blocks arachidonic acid release in a variety of mammalian cells. Biochim Biophys Acta (2001) 1.28
Increased plasma leptin concentration in end-stage renal disease. J Clin Endocrinol Metab (1997) 1.28
Functional differences between rat islets of ventral and dorsal pancreatic origin. J Clin Invest (1982) 1.27
Increased plasma gln and Leu Ra and inappropriately low muscle protein synthesis rate in AIDS wasting. Am J Physiol (1998) 1.27
Glucose-induced accumulation of inositol trisphosphates in isolated pancreatic islets. Predominance of the 1,3,4-isomer. Biochem J (1986) 1.25
Plasma glucose concentrations at the onset of hypoglycemic symptoms in patients with poorly controlled diabetes and in nondiabetics. N Engl J Med (1988) 1.25